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Abstract
Background: Changes in retinal fluid patterns associated with circumscribed choroidal hemangioma (CCH) have
not been investigated yet. A long-term follow-up study was performed to evaluate the changes of retinal fluid
patterns and treatment responses.
Methods: We retrospectively reviewed medical records of all CCH patients diagnosed between November 2005
and March 2017. Enrolled patients had visual symptoms, were treatment-naïve, and had been followed-up for more
than 2 years. Best corrected visual acuities (BCVA) and the presence, severity, and pattern change of the subretinal
fluid (SRF) and intraretinal fluid (IRF) in the macula on optical coherence tomography (OCT) were analyzed at initial
presentation and follow-up visits.
Results: Twenty-six patients were enrolled. All patients received one or more of the following treatments: PDT, TTT,
and intravitreal bevacizumab (Avastin) injection (IVB). Primary therapy consisted of PDT in 9 patients (34.6%), TTT in
7 patients (26.9%) and IVB in 10 patients (38.5%). At initial presentation, the SRF-only pattern was mostly observed.
Despite treatment, IRF occurred over time; eventually, advanced cystoid macular oedema (CME) developed. In
terms of retinal fluid reduction, PDT was most efficacious (9/9, 100%), and TTT and IVB showed moderate efficacy
(TTT: 4/7, 57.1%; IVB: 5/10, 50%) as a primary therapy. After advanced CME developed, IVB and TTT showed no or
minimal effect (TTT: 0/1, 0%; IVB: 0/19, 0%), and PDT was the only effective therapy (6/10, 60%).
Conclusion: The pattern of retinal fluid accompanied by CCH evolved from an SRF-only pattern initially to an
advanced CME pattern. The effectiveness of treatments decreased over time, and advanced CME generally showed
resistance to treatments. PDT would be the most recommended treatment.
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Background
Circumscribed choroidal hemangioma (CCH) is a benign
tumour, and asymptomatic CCH does not require treat-
ment. Associated serous retinal detachment and cystoid
macular edema (CME) are common findings in
symptomatic CCH. Various treatment modalities includ-
ing photodynamic therapy (PDT) [1–7], transpupillary
thermotherapy (TTT) [8–10], anti-vascular endothelial
growth factor (VEGF) injections [8], lens-sparing external
beam radiotherapy [11, 12], plaque brachytherapy [13, 14],
proton beam therapy [15], stereotactic radiosurgery [16],
laser photocoagulation [11], and oral propranolol [17]
have been applied for treating CCH related symptomatic
fluids. Although various treatments have been explored,
according to recent studies, PDT has emerged as the
treatment of choice with high rates of tumour regression,
fluid resorption and minimal complications [4–7, 18].
In a large study, serous retinal detachment and CME
were reported in 81 and 17% of patients at initial
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presentation, respectively [19]. However, there have been
no longitudinal observational studies to investigate
changes in retinal fluid patterns associated with CCH.
The aim of this study was to evaluate the changes in
retinal fluid patterns, the response to various treatment
modalities, and the prognosis of visual acuity in patients
with CCH through a long-term follow-up.
Methods
We retrospectively reviewed the medical records of all
patients diagnosed with CCH at Yonsei University Sever-
ance Hospital between November 2005 and March 2017.
Patients who had visual symptoms, were treatment-naïve
at initial presentation, and were followed-up for more
than 2 years were enrolled. CCH was diagnosed based
on fundus examination, indocyanine green angiography
(ICGA), and ultrasonography. This study was approved
by the Institutional Review Board at Yonsei University
Medical Center (Reference No. 4–2017-0955) and ad-
hered to the tenets of the Declaration of Helsinki.
Baseline demographic data, including age, sex, general
and ocular history, symptoms, follow-up duration, and
series of treatments were recorded.
Initial assessment of patients included the minimal
angle of resolution (logMAR) best-corrected visual acu-
ity (BCVA) measurement using the Snellen visual acuity
chart, slit-lamp biomicroscopy, dilated fundus examin-
ation, fundus photography, fluorescein angiography and
ICGA, B-scan ultrasonography, and optical coherence
tomography (OCT) (Stratus III OCT, Carl Zeiss, Dublin,
California, USA; or Spectralis HRA +OCT, Heidelberg
Engineering, Heidelberg, Germany).
Tumour size and location, and distance to the foveola
and optic disc margin were measured using B-scan ultra-
sonography, fundus photography, and OCT.
BCVA, and the presence, severity, and pattern change of
the retinal fluid on OCT were observed during every
follow-up visit. Changes in retinal fluid following each
treatment were evaluated qualitatively and quantitatively.
The pattern of retinal fluid in the macula was divided
into three types; subretinal fluid (SRF) only; SRF / intrar-
etinal fluid (IRF) combined; and advanced (well orga-
nized) CME pattern consisting of severe IRF.
Treatment modalities
“All patients received one or more of the following treat-
ments: PDT, TTT, and intravitreal bevacizumab (Avas-
tin) injection (IVB).”
PDT was performed with standard equipment under
standard conditions. An 83-s laser spot at 689 nm (50 J/
cm2) coupled with intravenous verteporfin was used to
treat the entire CCH. Verteporfin 6 (typical) or 12 mg/
m2 (enhanced) was injected. The area of treatment was
determined by the size of the tumour measured using
ICGA. When the target area exceeded the maximum
spot size, treatments were repeated several times with-
out overlap.
TTT was performed under topical anesthesia via a di-
lated pupil. Patients were treated with an infrared diode
laser at 810 nm using a slit-lamp biomicroscope delivery
system. Each tumour was covered entirely with conflu-
ent laser spots, with the power ranging from 200 to 500
mW and spot size between 1200 and 3000 μm to induce
a slight color change with 1 min of exposure at each
spot. An area of 1-disc diameter (DD) around the
foveola and 1 DD around the disc margin were spared
during TTT in all cases.
Using an aseptic technique, bevacizumab (Avastin)
1.25 mg was injected 3.0 or 3.5 mm posterior to the lim-
bus through the pars plana using a 30-gauge needle in
the operating room.
Comprehensive evaluation of therapeutic response
Indications for treatment included serous macular de-
tachment (SMD) and CME causing visual symptoms.
When the fluid was fully resolved, no further treatment
was performed. When the treatment effect was insuffi-
cient or the fluid recurred, treatment was performed
again. When the treatment appeared to be ineffective or
an additional session using the same treatment modality
had the potential to induce retinal damage, a different
therapy was trialled. OCT was performed within 8 weeks
after each treatment. The treatment effect was evaluated
after 4 weeks in cases where IVB was administered. In
cases where patients received PDT or TTT treatment,
monitoring continued for at least 8 weeks.
During long-term follow-up, the types, order, and
number of treatments administered varied among pa-
tients. For analysis, the series of treatments were simpli-
fied. The efficacy of each treatment was assessed by
whether it increased or decreased the amount of SRF
and/or IRF on OCT. Efficacy was classified into three
groups and was numerically parameterized.
A reduction of less than 20%, or no change, in the
fluid following treatment was classified as ‘minimal or
none’ and parameterized as 0 point. For cases with a 20
to 80% reduction following treatment, these were classi-
fied as ‘partial’ responses and parameterized as 0.5 point.
For cases with an 80 to 100% reduction, these were clas-
sified as ‘almost or complete’ responses and parameter-
ized as 1 point. The mean score for several sessions of a
single treatment modality was obtained when the same
treatment modality was applied continuously in a series.
For example, if IVBs were performed 5 times consecu-
tively and the effects were #1: almost or complete; #2:
partial; #3: minimal or none; #4: minimal or none; and
#5: partial, the overall mean efficacy of IVB was 0.4 (1.0
+ 0.5 + 0 + 0 + 0.5 / 5 = 2.0 / 5).
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Statistics
Statistical analyses were performed using SPSS 23.0 soft-
ware (IBM Corp., Armonk, NY, USA). Averages are re-
ported as the mean ± standard deviation (SD). When
comparing the paired mean at different points within an
individual, a paired t-test was performed. A p-value of <
0.05 was considered statistically significant.
Results
All enrolled patients had symptomatic CCH and were
treatment-naïve. All patients received PDT and/or TTT
and/or IVB for serous macular detachment and CME. Pa-
tient demographics and clinical data are shown in Table 1.
Twenty-six patients were enrolled. The mean ± SD
(minimum to maximum) follow-up duration was 63.68
± 30.10 (range, 27.77 to 128.52) months. The median
and interquartile ranges of follow-up duration were
58.33 months and 35.73 to 82.02 months, respectively.
Seventeen patients were followed-up for 48 months and
9 patients were followed up for 24 to 48months.
The mean age was 49.26 ± 10.07 years. There were 16
males and 10 females. The mean largest base diameter
(LBD) and height of the tumour were 8.70 ± 1.73 (range,
4.56–11.86) and 3.31 ± 1.02 (range, 1.52–5.21) mm, re-
spectively. Twelve tumours involved the subfoveal area
and 14 tumours were located in the extrafoveal area.
Pattern change of retinal fluid related with CCH
The pattern changes in retinal fluid associated with
CCH are presented in Fig. 1. The pattern of retinal fluid
at initial presentation was SRF-only in 19 patients
(73.1%), SRF and IRF combined in 4 patients (15.4%),
and advanced CME in 3 patients (11.5%).
Over time, the pattern of retinal fluid evolved. Among
the patients with more than 48months’ follow-up, the ret-
inal fluid pattern progressed to an advanced CME pattern
in 9 of 17 patients (52.9%), changed to SRF and IRF com-
bined pattern in 6 patients (35.3%), and remained as
SRF-only in only 2 patients (11.8%). IRF occurred in 2 out
of 9 (22.2%) patients with 24 to 48months’ follow-up.
Overall, the SRF-only pattern was observed mostly at
initial presentation, whereas IRF occurred over time.
The advanced CME pattern was observed mostly with
patients who had long-term follow-up.
There was no association between the use of certain
treatments and the development of advanced CME.
Therapeutic effect on SRF or IRF according to treatment
modalities
We examined the therapeutic response of retinal fluid
according to each treatment modality performed as a
primary therapy or secondary therapy.
Primary therapy was PDT in 9 patients (typical 7; en-
hanced 2), TTT in 7 patients and IVB in 10 patients. For
PDT cases, ‘almost or complete’ response (mean score
1.0) was observed in 8 of 9 patients (typical 6; enhanced
2) (88.9%) and a ‘partial’ response (mean score 0.5) was
observed in 1 patient (11.1%). For TTT cases, 3 patients
(42.9%) showed ‘almost or complete’ resolution (mean
score 1.0), 1 (14.3%) showed ‘partial’ resolution (mean
score 0.5) and 3 (42.9%) showed ‘minimal or no’ effect
(mean score 0.0). In IVB cases, 2 patients (20%) showed
‘partial to almost’ resolution (mean score 0.75), 3 pa-
tients showed ‘partial’ response (mean score 0.5) (30%)
and 5 patients (50%) showed ‘minimal or no’ effect
(mean score 0.0). PDT had a good therapeutic effect,
and TTT and IVB showed modest therapeutic effects on
retinal fluid with CCH.
Secondary therapy was performed as follows: PDT in
10 patients (typical 5; enhanced 5), TTT in 1 patient and
IVB in 7 patients. TTT and IVB showed ‘minimal or no’
effect (mean score 0.0) in all patients. PDT showed ‘al-
most or complete’ resolution (mean score 1.0) in 5 pa-
tients (typical 2; enhanced 3) (50%), ‘partial to almost’
resolution (mean score 0.75) in 2 patients (typical 2)
(20%) and ‘partial’ response (mean score 0.5) in 3 pa-
tients (typical 1; enhanced 2) (30%). Typical PDT and
enhanced PDT showed similar effects. For all 3 treat-
ment modalities, there was a lower therapeutic effect
when they were applied as a secondary therapy com-
pared to when they were used as a primary therapy.
Nine patients showed advanced CME during the
follow-up period. IVBs were performed 19 times in 6 pa-
tients and showed ‘minimal or no’ effect (mean score 0.0)
in all cases. TTT was performed once in 1 patient and
showed ‘minimal or no’ effect (mean score 0.0). PDTs
were performed 10 times (typical 6 times; enhanced 4
times) in 5 patients. Four out of 10 (40%) sessions showed
‘almost or complete’ response (mean score 1.0) and 2 out
of 10 (20%) showed a ‘partial’ response (mean score 0.5),
and 4 out of 10 (40%) showed ‘no or minimal’ effect (mean
score 0.0). Enhanced PDT was not superior to typical
PDT. IVB and TTT had no effect on advanced CME.
Therapeutic effect on BCVA according to treatment
modalities
Results from final BCVA compared with initial BCVA
according to primary and secondary therapeutic modal-
ities are presented in Table 2. Final BCVA improved in 9
out of 26 patients (34.6%), remained stable in 4 patients
(15.4%), and deteriorated in 13 patients (50%) compared
to initial BCVA. The mean final BCVA was lower than
the initial BCVA with marginal significance [logMAR
(Initial vs. Final): 0.79 ± 0.54 vs. 1.10 ± 0.91 (p = 0.064)].
We further examined BCVA changes according to
each treatment modality. Among 17 patients followed
up over 48 months, as primary and secondary therapies,
8 patients received PDT at least once and 8 patients
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received TTT at least once. There was no significant
difference in age, tumour position, and tumour size
between the PDT group and the TTT group. Compar-
ing final BCVA with initial BCVA, in PDT cases, 4
out of 8 patients (50%) showed an improvement in
BCVA, 1 patient (12.5%) remained stable and 3 pa-
tients (37.5%) deteriorated. Whereas, all patients that
received TTT showed deterioration in their BCVA (8/
8 = 100%).
All 9 patients who were followed up for 24 to 48
months received PDT plus IVB (or IVB plus PDT).
Comparing final BCVA with initial BCVA, 5 out of 9 pa-
tients (55.6%) showed improvement in their BCVA, 2
patients (22.2%) remained stable, and 2 patients’ (22.2%)
BCVA deteriorated. The mean final BCVA was improved
when compared to the initial BCVA, however, this was
not statistically significant (p = 0.473).
Cases
We present two representative cases demonstrating the
pattern of change in retinal fluid associated with CCH.
In both cases, SRF-only patterns were noted at initial
presentation and over time, SRF transitioned to IRF,
eventually progressing to advanced CME, despite various
treatment efforts. In one case (Fig. 2; Case 7), the retinal
fluid responded well to PDT initially, however, the fluid
eventually returned and subsequently progressed to the
advanced CME pattern. In the other case (Fig. 3; Case
6), the retinal fluid was completely resolved following
multiple treatments with PDT, and there was no recur-
rence during the more than 3 years of follow-up.
Discussion
We investigated the changes in retinal fluid patterns and
the therapeutic response to various treatment modalities
Fig. 1 Changes in retinal fluid patterns over time in patients with circumscribed choroidal hemangioma. Among enrolled patients, patterns of
retinal fluid at initial presentation were as follows: SRF-only in 19 patients (19/26, 73.1%), SRF and IRF combined in 4 patients (4/26, 15.4%), and
advanced cystoid macular edema (CME) in 3 patients (3/26, 11.5%). Over time, changes in the pattern of retinal fluid occurred. The patterns of
retinal fluid at last presentation were as follows: Advanced CME in 9 of 26 patients (9/26, 34.6%), SRF and IRF combined in 8 patients (8/26,
30.8%), and remained as SRF-only in 9 patients (9/26, 34.6%)
Table 2 Final best corrected visual acuity (BCVA) compared with initial BCVA according to primary and secondary therapeutic modalities
BCVA change
Treatment modality Improved Stable Worsen Total number
P + A (A + P) 5 (3 + 2) (45.45%) 1 (0 + 1) (9.09%) 5 (3 + 2) (45.45%) 11
P 4 (1 + 3) (66.67%) 2 (1 + 1) (33.33%) 6
A 1 (1 + 0) (100%) 1
T + A (A + T) 6 (6 + 0) (100%) 6
T 2 (2 + 0) (100%) 2
Total number of patients (number of patients followed up over 48 months + number of patients followed up between 24 to 48 months)
BCVA best corrected visual acuity, T transpupillary thermotherapy, P photodynamic therapy, A intravitreal bevacizumab (Avastin) injection
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in patients with symptomatic CCH who underwent
long-term follow-up. There have been no studies that
focus on changes in retinal fluid patterns associated with
CCH.
The SRF-pattern was mainly observed in the early
stage, followed by SRF and IRF combined, and eventu-
ally, an advanced CME pattern was established over
time. During the follow-up period, advanced CME oc-
curred regardless of the treatment modality. Despite
treatment efforts, the occurrence of CME could not be
prevented. Patients with advanced CME at initial presen-
tation may be assumed to have had long-lasting retinal
fluid along with CCH.
The pathophysiology of CME in CCH is poorly under-
stood. CME often occurs due to breakdown of the inner
blood–retina barrier and is not an uncommon manifest-
ation of diabetic retinopathy, retinal vein occlusion, and
inflammatory diseases of the posterior segment. Less
commonly, CME is the result of incompetence of the
outer blood–retina barrier [20]. In long-standing central
serous chorioretinopathy, some eyes will develop CME
[21, 22]. In the case of CME following a long lasting
SRF, it may be related to alteration of the external limit-
ing membrane (ELM), which is the linear aggregate of
junctions between the outer portions of Müller cells and
the inner segments of the photoreceptors. The ELM
Fig. 2 A representative case of circumscribed choroidal hemangioma showing the change in retinal fluid over time. A 48-year-old woman (Case
7) presented with blurred vision of the right eye. Her initial best corrected visual acuity (BCVA) was 0.63. (a) On fundus photography, an orange
and red-colored subretinal mass was observed supero-temporally to the macula. (b) B-scan ultrasonography showed a hyperreflective mass with
a height of 4.77 mm and base diameter of 11.07 mm. (c) Shallow subretinal fluid involving the fovea was observed along with elevation of the
choroid by a mass lesion on optical coherence tomography. (d) During the first 6 months, despite a single intravitreal bevacizumab (IVB) injection,
the subretinal fluid (SRF) increased. Thereafter, a second IVB injection and single session of transpupillary thermotherapy (TTT) were performed;
however, there was no significant improvement in therapeutic effect. Subsequently, a single session of photodynamic therapy (PDT) and
enhanced PDT were performed and the SRF completely resolved. However, the subsequent BCVA was 0.04. (e) After 2 years of follow-up, SRF and
intraretinal fluid then developed. (f) Six months later, an advanced cystoid macular edema pattern was observed
Lee et al. BMC Ophthalmology          (2018) 18:321 Page 6 of 8
may serve as a barrier for fluid leaving the retina to be
pumped from the subretinal space by the retinal pigment
epithelium. When the ELM is intact, fluid from below
the retina can cause serous detachment of the retina,
and when the ELM is defective, there may be passage of
fluid into the outer retina [23].
Among the three treatment modalities reported in this
study, PDT showed the greatest treatment efficacy, and
TTT and IVB showed moderate efficacy for retinal fluid re-
duction as a primary therapy. As secondary therapies, the
efficacy of all 3 treatment modalities was reduced. As the
retinal fluid with the tumour became older or recurred, it
appears to have become refractory to various treatments.
Early and appropriate treatment of CCH is important.
Several years ago, our group reported the efficacy of IVB
in the treatment of 12 symptomatic CCH patients [8]. IVB
led to the resolution of serous macular detachment and im-
provement of visual acuity in 5 of 9 patients. However, its
duration of treatment effectiveness seemed to be relatively
short. Similar results were observed in this study. Although
IVB may have the advantages of greater feasibility and
lower cost than PDT or TTT, IVB monotherapy seems to
be insufficiently effective to manage CCH completely. Re-
peated IVB therapy should not delay PDT therapy.
Our study findings may have clinical significance because
different therapeutic responses were observed depending on
the retinal fluid pattern. CME has been considered a poor
prognostic factor in CCH [2, 24]. A previous study by our
group showed that CME does not respond effectively to IVB
[8]. In this study, after formation of advanced CME, IVB was
not effective in all 19 applications, and PDT was effective in
half of the cases. The Shields group also previously reported
a case where PDT was effective in CME with CCH [24].
It is not clear whether the treatment response to ad-
vanced CME is poor due to inherent characteristics of
the CME or as a result of long-standing CCH. Alterna-
tively, the poor response may be due to the long-term
presence of retinal fluid or damage to the structure of
the retinal by previous treatments. Each of these reasons
alone or in combination may explain this observation.
According to recent research in CCH treatment, PDT
has emerged as the treatment of choice with high rates of
tumour regression, fluid resorption, and minimal complica-
tions [4–7, 18]. Our findings agree with this research as
PDT showed the most promising results not only as a pri-
mary therapy, but also after the formation of advanced
CME.
Conclusion
Among patients with long-term follow-up, over half of
the patients treated with PDT showed improvement in
their BCVAs. In conclusion, PDT appears to be an ef-
fective treatment for symptomatic retinal fluid associated
with CCH.
Fig. 3 A representative case of circumscribed choroidal hemangioma where complete resolution of advanced cystoid macular edema (CME) occurred using
photodynamic therapy (PDT). A 44-year-old woman (Case 6) presented with blurred vision of the left eye. Her initial best corrected visual acuity (BCVA) was
0.63. At initial presentation, minimal subretinal fluid (SRF) was present. (a) After 8months, the BCVA decreased to 0.025, and a large serous retinal detachment
(SRD) developed. A single intravitreal bevacizumab injection was performed, and the SRD completely resolved. (b) After 28months, SRF and intraretinal fluid
(IRF) occurred. A second intravitreal bevacizumab injection was performed; however, the fluid only partially resolved. (c) Three months later, advanced CME
developed. Two subsequent PDTs were performed, and complete resolution occurred. Thereafter, there was a minor recurrence of SRF and IRF, and enhanced
PDT was performed, and the fluid was again completely resolved. (d) After more than 3 years of follow-up, the fluid did not recur
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